S
Sancilio and Company
Sancilio and Company develops biopharmaceutical supplements and products.
About Sancilio and Company
Micelle BioPharma operates as an integrated specialty pharmaceutical company, leveraging its proprietary Advanced Lipid Technologies (ALT) platform. This technology is engineered to improve the body's absorption and utilization of lipophilic compounds, which includes substances like fatty acids, hormones, various vitamins, and active pharmaceutical ingredients (APIs). The company was formerly known as Sancilio and Company, founded in 2005 by the serial entrepreneur Dr. Frederick D. Sancilio, who holds bachelor's, master's, and doctoral degrees in chemistry from Rutgers University. Dr. Sancilio's extensive career in the pharmaceutical industry includes positions at major companies like GSK (formerly Burroughs-Wellcome), Schering-Plough, and Hoffmann-LaRoche before he founded his first company in 1979.
The original company, Sancilio Pharmaceuticals Company, Inc., filed for bankruptcy in 2018, and its assets, including the ALT platform, a Phase III-ready product for sickle cell disease (Altemia), and its manufacturing facilities, were acquired by Micelle BioPharma, Inc. in August 2018. The predecessor firm had developed several products for preventing dental caries in children and treating essential fatty acid deficiencies. The business model encompasses drug development, manufacturing of soft gel capsules, and out-licensing its ALT technology to third parties for developing their own drug applications. The company's focus is on creating drug candidates for conditions such as Non-alcoholic fatty liver disease, Sickle Cell disease, and Short Bowel Syndrome. The ALT platform is designed to address the common issue of food effects on lipophilic drugs, thereby enhancing their bioavailability.
Dr. Sancilio, a seasoned pharmaceutical scientist, has been instrumental in the development of numerous drug products, holding over 40 patents. His entrepreneurial journey began after a robust research career where he learned from experienced scientists at Hoffman-LaRoche. This foundation led to the creation of several ventures, including one of the first Contract Research Organizations (CROs), Applied Analytical Industries (AAI), which later became aaiPharma. After a change of control at Sancilio Pharmaceuticals in 2017, Dr. Sancilio and his wife, Alex Sancilio, departed from the company. They later established Clearway Global, a consulting and product development firm focusing on areas like sickle cell disease and dementia, and re-established Sancilio and Company in 2019 to manage internal research programs and product offerings like the Omega Blu nutritional products line.
Source: Dealroom company dataNews
Open roles
Sancilio and Company in the Nashville ecosystem
The Sancilio and Company office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Signet Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sancilio and Company on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sancilio and Company on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

